These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 23166089

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Hähnke V, Hiss JA, Zettl H, Keppner S, Spänkuch B, Schneider P.
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [Abstract] [Full Text] [Related]

  • 3. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 4. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 15; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 5. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM, Shi Y, Quan J.
    ChemMedChem; 2015 Jan 15; 10(1):158-63. PubMed ID: 25196850
    [Abstract] [Full Text] [Related]

  • 6. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4587-92. PubMed ID: 20594842
    [Abstract] [Full Text] [Related]

  • 7. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1247-50. PubMed ID: 22172702
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX, Huang J, Liu M, Xu YG, Jiang C.
    Arch Pharm (Weinheim); 2015 Jan 15; 348(1):2-9. PubMed ID: 25430493
    [Abstract] [Full Text] [Related]

  • 10. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chembiochem; 2009 May 04; 10(7):1145-8. PubMed ID: 19350612
    [Abstract] [Full Text] [Related]

  • 11. Vanillin-derived antiproliferative compounds influence Plk1 activity.
    Carrasco-Gomez R, Keppner-Witter S, Hieke M, Lange L, Schneider G, Schubert-Zsilavecz M, Proschak E, Spänkuch B.
    Bioorg Med Chem Lett; 2014 Nov 01; 24(21):5063-9. PubMed ID: 25304894
    [Abstract] [Full Text] [Related]

  • 12. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y.
    Bioorg Med Chem; 2013 Feb 01; 21(3):608-17. PubMed ID: 23276450
    [Abstract] [Full Text] [Related]

  • 13. Developing polo-like kinase 1 inhibitors.
    Huang X, Xie Z, Liao C.
    Future Med Chem; 2020 May 01; 12(10):869-871. PubMed ID: 32233804
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2969-74. PubMed ID: 21470862
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting polo-like kinase: learning too little too late?
    Olmos D, Swanton C, de Bono J.
    J Clin Oncol; 2008 Dec 01; 26(34):5497-9. PubMed ID: 18955441
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J, Wang Y, Li Y, Xu L, Cao D, Song S, Damaneh MS, Wang X, Meng T, Chen YL, Shen J, Miao Z, Xiong B.
    Eur J Med Chem; 2017 Sep 08; 137():176-195. PubMed ID: 28586718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.